National Advisory Committee on Immunization (NACI): Membership and representation

The National Advisory Committee on Immunization (NACI) is a national advisory committee of experts in the fields of pediatrics, infectious diseases, immunology, pharmacy, nursing, epidemiology, pharmacoeconomics, social science and public health. NACI has been providing guidance on the use of vaccines currently or newly approved for use in Canada to the Government of Canada since 1964. The Committee reports to the Vice-President of the Infectious Disease Prevention and Control Branch, and works with staff of the Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada to provide ongoing and timely medical, scientific and public health advice.

NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are included in published literature reviews, statements and updates. NACI recommendations are also published in the Canadian Immunization Guide. Email updates are available through our mailing list.

Membership

Chair

Dr. Shelley Deeks

Office of the Chief Medical Officer of Health
Halifax, Nova Scotia

Dr. Shelley Deeks is the Deputy Chief Medical Officer of Health at the Nova Scotia Office of the Chief Medical Officer of Health. She has a long-standing interest and passion for communicable disease control and immunization in general, and vaccine safety in particular, with over 120 peer-reviewed publications. Aside from her membership in the National Advisory Committee on Immunization, she is a past Chair of the World Health Organization's (WHO's) Immunization Practices Advisory Committee. Dr. Deeks holds Fellowships in Public Health in both Canada and Australia and completed the Canadian Field Epidemiology Program. She has over 20 years' experience as a public health physician and has worked at all levels of the public health system in Canada, and at the national level in Australia.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates

Is Ontario prepared for the return of measles? (Co-Investigator)

Canadian Institutes of Health Research

Institution

$100,000-500,000

One-time event

Date interest arose:
Oct 1, 2019

Date interest ended:
Sept 30, 2022

Burden, cost, and development of asthma related to severe RSV infections

SickKids, Canadian Institutes of Health Research, Institute of Human Development, Child and Youth Health

Institution

$100,000-500,000

One-time event

Date interest arose:
Feb 2019

Date interest ended:
Feb 2022

Infant susceptibility to measles: the impact of maternal vaccination on maternal and infant antibody levels and implications for public health policy in Canada (Co-Investigator)

Physicians’ Services Incorporated Foundation

Institution

$100,000-500,000

One-time event

Date interest arose:
Sept 2017

Date interest ended:
Aug 2020

Mind the gap: Duration of protection from measles maternal antibody in Canadian infants – generating evidence to update policy (Co-Investigator)

Canadian Institutes of Health Research

Institution

$100,000-500,000

One-time event

Date interest arose:
Apr 2017

Date interest ended:
Apr 2020

Vaccination & screening for control sexually transmitted infections (STIs) and STI-related cancers

Canadian Institutes of Health Research

Institution

$500,000-1,000,000

One-time event

Date interest arose:
Apr 2017

Date interest ended:
Apr 2020

Improved Immunization Coverage Initiative - Recent newcomers

Canadian Institutes of Health Research

Institution

$100,000-500,000

One-time event

Date interest arose:
Feb 2017

Date interest ended:
Feb 2019

HPV Screening & Vaccination in Underserved Population. Advancing Evidence-based Vaccination & Screening Delivery for Men who have Sex with Men and People living with HIV (Co-Investigator)

Canadian Institutes of Health Research

Institution

$100,000-500,000

One-time event

Date interest arose:
Nov 2017

Date interest ended:
Oct 2018

Un-immunized children in Ontario: how many, where and why? (Co-Investigator)

Public Health Ontario

Institution

$10,000-50,000

One-time event

Date interest arose:
Apr 2017

Date interest ended:
Mar 2018

Maximising the impact of immunization programs in Canada: bridging the gap between research and policy (Co-Investigator)

Canadian Institutes of Health Research

Institution

$5,000-10,000

One-time event

Date interest arose:
Feb 2017

Date interest ended:
Jan 2018

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Deputy Chief Medical Officer of Health Employee Province of Nova Scotia – Department of Health and Wellness Full-Time position Date interest arose: Feb 2021
Date interest ended: Ongoing
Canadian Federal/Provincial/Territorial Special Advisory Committee (SAC), Member Public Health Agency of Canada >1 time Date interest arose: Feb 2021
Date interest ended: Ongoing
Chief Health Protection Officer, Employee Public Health Ontario Full-Time position Date interest arose: Aug 2009
Date interest ended: Jan 2021
WHO SAGE Polio Working Group Member Work Health Organization >1 time Date interest arose: Oct 2017
Date interest ended: Ongoing
Vaccine Innovation Prioritisation Strategy (VIPS) Steering Committee, Member GAVI, the vaccine alliance >1 time Date interest arose: Oct 2018
Date interest ended: Oct 2020

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
New Vaccines in the next 2-5 years. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 4, 2018
Safety in Numbers: A Collaborative Workshop to Build Capacity in the Surveillance and Management of Adverse Events following Immunization. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 6, 2018
Advancing Evidence-Based Human Papillomavirus Vaccination Deliver for Gay, Bisexual and Other Men who have Sex with Men and People living with HIV. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 6, 2018
Where is the risk? Identification of geospacial hotspots of un-immunized children in Ontario. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 5, 2018
Immunization status and other characteristics of Ontario students with non-medical exemptions: 2016-2017 school year. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 5, 2018
A systematic review on the risk of herpes zoster and complications in immunocompromised adults. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 5, 2018
Effectiveness of an ‘outbreak dose’ of MMR vaccine during a mumps outbreak in two First Nations communities in Northern Ontario. (Canadian Immunization Conference 2018. Ottawa, ON) N/A N/A N/A One-time event Dec 6, 2018
Sero-epidemiology of Varicella in Ontario, 2013-2014. (The Ontario Public Health Convention. Toronto, ON) N/A N/A N/A One-time event Mar 21, 2018
Measles Antibody Levels in Children Less than 1 Year: Assessment of Waning Immunity. (The Ontario Public Health Convention. Toronto, ON) N/A N/A N/A One-time event Mar 21, 2018
The epidemiology of the increase in mumps activity in Ontario in 2017. (The Ontario Public Health Convention. Toronto, ON) N/A N/A N/A One-time event Mar 21, 2018

6. Sponsored travel

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates

Travel to Geneva for VIPS meeting

GAVI, the vaccine alliance

Directly to the researcher

$1,000-5,000

>1 time

Date interest arose: Nov 2018

Date interest ended: Ongoing

WHO SAGE Polio Working Group

World Health Organization

Directly to the researcher

$1,000-5,000

>1 time

Date interest arose: Oct 2017

Date interest ended: Ongoing

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Vice-chair

Dr. Robyn Harrison

Alberta Health Services
Grey Nuns and University of Alberta Hospitals

Dr. Robyn Harrison is an Infectious Disease Specialist who works in Edmonton, Alberta. She is a Communicable Disease Consultant for the province wide Alberta Health Services Workplace Health and Safety Program (a position she has held since 2009). She has also served as consultant for the Covenant Health Alberta Occupational Health and Safety Program (2008-2014). Dr. Harrison is keenly interested in policy development and support for clinicians to prevent infection transmission in healthcare settings. She is a member of the Alberta Advisory Committee on Immunization, and she participates in infection prevention working groups in the province of Alberta, including past work on pandemic influenza H1N1 in 2009, and avian influenza is 2014. At a national level, she is working with the Public Health Agency of Canada as a member of the Prevention and Control of Occupational Infections in Health Care Settings Guideline Working Group to update and disseminate national evidence-based infection prevention and control (IPC) guidance.

Dr. Harrison obtained her medical degree at Dalhousie University, Nova Scotia; and she completed her Internal Medicine and Infectious Diseases subspecialty training at the University of Alberta. Most recently she completed an MSc in the combined areas of Public Health and Epidemiology through the London School of Hygiene and Tropical Medicine, England.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid or voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Communicable Disease Consultant Alberta Health Services >1 time Date interest arose: 2009
Date interest ended: Ongoing
Alberta Advisory Committee on Immunization Alberta Health >1 time Date interest arose: 2015
Date interest ended: Ongoing

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travel

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates

NACI PHAC supported travel to Ottawa

PHAC

N/A

<$1,000

>1 time

Date interest arose: 2017

Date interest ended:

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Members

Dr. Melissa Andrew

Dalhousie University
Halifax, Nova Scotia  

Melissa K. Andrew is Professor of Geriatric Medicine at Dalhousie University in Nova Scotia, Canada. She did a Masters of Public Health at the London School of Hygiene and Tropical Medicine and completed her Interdisciplinary PhD at Dalhousie University on frailty and social vulnerability in older adults. She is an Associate Member of the Canadian Centre for Vaccinology and co-Principal Investigator of the Canadian Immunization Research Network Serious Outcomes Surveillance (SOS) Network, studying how frailty impacts influenza and COVID-19 vaccine effectiveness and clinical outcomes, especially in older people. She has worked on including frailty in vaccine clinical trials and serves on the Scientific and Executive Committees of the Global Influenza Hospital Surveillance Network.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples:

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
I was the Principal Investigator of research studies on frailty in relation to influenza outcomes, and surveys of older adults' experiences with influenza andvaccination Canadian Frailty Network partnership with Sanofi Institution $50,000- 100,000 One-time event Date interest arose:  2017
Date interest ended: 2019
I have been an investigator on surveys of middle aged and older adults' knowledge, attitudes and beliefs, and experiences with influenza like illness impacting their function and activities. Two rounds of research surveys completed (one per year). Sanofi Institution $50,000-100,000 >1 time Date interest arose: 2019
Date interest ended: Final paper being submitted Oct 2021
I was the Principal Investigator of research studies on frailty in relation to zoster vaccine efficacy – a secondary analysis of data from two large RCTs. Two published papers to date, one in submission. GSK Institution $100,000- 500,000 One-time event Date interest arose: 2018
Date interest ended: Final paper on frailty index validation, to promote use in other clinical trials, being submitted Oct 2021
I am collaborating as an investigator to add a frailty index measure to a COVID vaccine RCT. No funding or payments. Janssen N/A N/A One-time event Date interest arose: 2020
Date interest ended: Ongoing
I am a PI on a grant the burden of RSV among hospitalized Canadian adults; conducted through the SOS Network GSK Institution $500,000- 1,000,000 One-time event Date interest arose: Jan 2019
Date interest ended: Ongoing
I am an investigator on a grant: Hospitalized Pneumococcal Pneumonia in Canadian Adults Merck Institution >$1,000,000 One-time event Date interest arose: Jan 2019
Date interest ended: Ongoing
Public Health Agency of Canada funding for influenza and COVID- 19 surveillance; run though Public Works Canada PHAC
contract
Institution >$1,000,000 >1 time Date interest arose: 2018
Date interest ended: Ongoing
Global Influenza Hospital Surveillance Network – co- Principal Investigator of Canadian site Fondation de France Institution $100,000- 500,000 >1 time Date interest arose: 2017
Date interest ended: Ongoing
Investigator on a grant studying pneumococcal disease in hospitalized adults Pfizer Institution >$1,000,000 One-time event Date interest arose: 2015
Date interest ended: 2019

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Ad hoc participation in advisory boards on COVID vaccine (and hesitancy), Pneumococcal vaccines: Nov 2019,
Nov 2020, one meeting spread over virtual sessions in Oct, Nov 2021 and Feb 2022. No ongoing commitment
between meetings.
Pfizer >1 time Date interest arose: Nov 2019
Date interest ended: Nov 2021, Feb 2022
Ad hoc participation in advisory boards on influenza and COVID vaccines: Feb 2019,
Oct 2020, May 2021,
Sept 2021; No ongoing commitment between meetings.
Sanofi >1 time Date interest arose: Feb 2019
Date interest ended: Sept 2021
Ad hoc participation in advisory boards on influenza vaccines for
(older) adults: Feb 2021, June 2021
Seqirus >1 time Date interest arose: Feb 2021
Date interest ended: June 2021
Consulting to help lead a systematic review on the humanistic sequellae
of influenza
Sanofi One-time event Date interest arose: Jan 2020
Date interest ended: Apr 2020

Please provide any additional comments, if applicable:

My interest in participating in advisory boards and consulting is to promote the importance of specifically considering the needs of older adults (e.g., immune dysregulation, frailty and functional impacts) in the development and testing of vaccines.

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Internal Conference on Frailty and Sarcopenia Research symposium panel on the impact of influenza on older adults, my presentation entitled: “Pathophysiolog y of frailty and implications for influenza infection, outcomes and response to vaccination”. Meeting was intended to be in person, transitioned to virtual. Sanofi Directly to the researcher $1,000-5,000 One-time event Mar 2020
ESWI panel on Influenza and COVID-19: The Diseases Burden and Prospects for Vaccination”, my presentation entitled: “The burden of influenza and
COVID-19”
Sanofi Directly to the researcher $1,000-5,000 One-time event Date interest arose: Aug 2021
Date interest ended: Dec 2021

Please provide any additional comments, if applicable:

In all invited presentations (including public webinars from advocacy groups and industry sponsored seminars/panels at conferences), I develop my own slides and materials largely based on my research. I have never used industry provided slide decks or promoted any specific products. I do not do speakers bureau presentations, or presentations that advocate for any specific products. My focus is on the importance of frailty and function in relation to older adults’ vulnerability to and outcomes of illness, and how frailty and age impact vaccine effectiveness where this is known.

I have presented many invited (symposium or panel) and investigator-initiated presentations at conferences that have addressed the impact of influenza and other vaccine preventable illnesses on older adults. Meetings include: OPTIONS X, Canadian Public Health Association Conference, Canadian Immunization Conference, Canadian Geriatrics Society, ID week.

6. Sponsored travel

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
ID week virtual conference registration fees reimbursed to present on the frailty and zoster study analyses GSK Directly to the researcher <$1,000 >1 time Date interest arose: Sept 2020
Date interest ended: Sept 2021
Travel expenses reimbursed to attend meetings of the Global Influenza Hospital Surveillance Network, or which I am a site investigator and member of the Scientific Advisory and Executive Committees GIHSN/
Fondation de France
Directly to the researcher $1,000-5,000 >1 time Date interest arose: 2017
Date interest ended: Ongoing (if/when travel and in-person travel resumes)
Registration fees reimbursed for attendance at the International Conference on Frailty and Sarcopenia Research, Toulouse (virtual) Sanofi Directly to the researcher $1,000-5,000 One-time event Date interest arose:
Date interest ended: Mar 2020

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
I have written many papers which advocate for improved vaccination development and uptake in older adults. No specific products advocated for except for products that are already approved/recomme nded by NACI. No payments. N/A N/A >1 time Date interest arose:
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

I have advocated publicly for consideration of age and frailty in relation to vaccine development, evaluation and implementation, and on the need to improve vaccine development and coverage for adults and especially older adults. This has taken the form of published papers (e.g., commentaries and reviews) and numerous public presentations (e.g., webinars and round table participation for advocacy organizations like CanAGE, Global Coalition on Ageing, International Federation on Ageing, CanIMMUNIZE, Lung Association, Alzheimer Society, and the Canadian Frailty Network).

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Julie Bettinger

University of British Columbia
Vancouver, British Columbia

Dr. Julie Bettinger is an Associate Professor at the Vaccine Evaluation Center in the Department of Pediatrics at the University of British Columbia. She is an infectious disease epidemiologist whose research interests include vaccine safety and vaccine preventable diseases (specifically meningococcal and pneumococcal invasive infections), as well as attitudes and beliefs around immunization uptake and use. She is the data center director for the Canadian Immunization Monitoring Program, Active (IMPACT), an active surveillance network for vaccine preventable diseases and vaccine adverse events in 12 tertiary care pediatric hospitals across Canada and the principal investigator for CIRN's Canadian National Vaccine Safety (CANVAS) network, which monitors the safety of influenza vaccines each year.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates

Canadian Immunization Monitoring Program, Active Data center director
Executive committee member
Lead for invasive meningococcal surveillance and invasive pneumococcal surveillance

PHAC, GSK, Merck, Pfizer, Novartis

Institution Canadian Paediatric Society, which administers IMPACT

>$1,000,000

>1 time

Date interest arose: I have been continuously working on IMPACT since 2004

Date interest ended:

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates

“Vaccine Safety Monitoring in Canada.” and “Communication with Vaccine Hesitant Parents” and “Vaccine Hesitancy in Perspective.”

British Columbia Pediatric Society 

Directly to the researcher

<$1,000

One-time event

Date interest arose: Apr 11, 2019
Date interest ended: Apr 11, 2019

“Vaccine Hesitancy: It doesn’t matter if the COVID-19 vaccine works if nobody gets vaccinated.”  Medical Division, Pfizer Canada N/A N/A One-time event Date interest arose: Oct 7, 2020
Date interest ended: Oct 7, 2020
“COVID-19 vaccines: mRNA technology, efficacy, administration, and risks.” University of British Columbia Clinic Practice Guideline Rounds  Institution <$1,000 One-time event Date interest arose: Jan 20, 2021
Date interest ended: Jan 20, 2021
Various COVID-19 vaccine safety and hesitancy talks CME and conferences N/A N/A One-time event Date interest arose: 2020
Date interest ended: 2021

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Member: 2015-2019, co-chair 2020-present BC Immunization Committee N/A N/A >1 time Date interest arose: 2015
Date interest ended:
Member BC Centre for Disease Control New Vaccines Task Group N/A N/A >1 time Date interest arose: 2015
Date interest ended:
Member Medical Advisory Committee for the Meningitis Research Foundation of Canada N/A N/A >1 time Date interest arose: 2016
Date interest ended:

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Nicholas Brousseau

Institut national de santé publique du Québec
Québec, QC

Dr. Nicholas Brousseau is a specialist in preventive medicine and completed his education at Laval University in 2011. Following his education, he completed a research fellowship on vaccine-preventable diseases at Public Health England in London. Dr. Brousseau joined the Institut national de santé publique du Québec in 2015 and the Centre de recherche du CHU de Québec - Université Laval in 2019. He has been a Member of the Quebec Immunization Committee since 2016. He is also a Clinical Associate Professor at Laval University.

Dr. Brousseau conducts research on vaccine-preventable diseases. His areas of expertise are vaccination against pertussis, tetanus, pneumococcus, influenza and COVID-19 (immunogenicity, efficacy and impact of vaccination). He also conducts work on the optimization of vaccination services in Quebec. In 2020, he established a study on the seroprevalence of antibodies against the COVID-19 virus in health care workers in 10 hospital centers in Quebec.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Sub-investigator
Merck Cyomegalovirus Vaccine Clinical Trial Institution
Merck Institution $100,000-500,000 N/A Date interest arose: 2018
Date interest ended: 2020
Principle Investigator
Evaluation of the impact of changes to pertussis vaccination in Quebec
Quebec Ministry of Health and Social Services Institution Institution $100,000-500,000 N/A Date interest arose: 2020
Date interest ended: -
Sub-investigator
Pertussis Vaccination in Pregnant Women: Implementation and Evaluation of Different Vaccination Delivery Models
Quebec Ministry of Health and Social Services Institution Institution $100,000-500,000 N/A Date interest arose: 2020
Date interest ended: -
Principle investigator
Vaccination in pregnancy: acceptability to pregnant women and feasibility issues
Quebec Ministry of Health and Social Services Institution Institution $10,000-50,000 N/A Date interest arose: 2019
Date interest ended: -

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Vaccination consultant Institut national de santé publique du Québec (INSPQ) N/A Date interest arose: 2015
Date interest ended: Ongoing
Member of the Comité sur l'immunisation du Québec (CIQ) None (committee under the auspices of the INSPQ) N/A Date interest arose: 2016
Date interest ended: Ongoing

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Presentations at scientific conferences, including the Canadian Immunization Conference (CIC) N/A N/A N/A >1 time Date interest arose:
Date interest ended:

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
Media interviews to discuss Quebec Immunization Committee recommendations N/A N/A No income obtained N/A Date interest arose:
Date interest ended:

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Hélène Decaluwe

Research Centre of the Sainte-Justine University Hospital

Montreal, Quebec

Hélène Decaluwe is Associate Professor in the Immunology and Rheumatology Division of the CHU Sainte-Justine (Department of Pediatrics, University of Montreal) since 2010 and Clinician Scientist and outgoing Deputy Head of the Immune Diseases and Cancer Research Axis at the CHU Sainte-Justine Research Center. Dr. Decaluwe graduated from the Faculty of Medicine at McGill University and completed her residency in pediatrics at the CHU Sainte-Justine (University of Montreal). She then completed her training in pediatric clinical immunology at the Necker Enfants-Malades Hospital (Paris, France) with Professor Alain Fischer. Her research training includes a Master and a PhD degree in immunology at Pierre and Marie Curie University (Paris 6) carried out in the laboratories of Professor Jean-Laurent Casanova and Professor James Di Santo respectively. Clinical researcher supported by the Fonds de Recherche du Québec en Santé (FRQS), she has dedicated her career to resolving the mechanisms of T cell differentiation in health, infection and primary immune deficiencies. The primary focus of her research is to better understand the role of cytokines in the differentiation of T cells in health and disease, and to develop novel immunotherapeutic approaches that target cytokine-dependent pathways and inhibitory receptors expressed on T cells, to cure chronic viral infections and cancer. Supported by both national (Canadian Institutes of Health Research, National Institute of Health) and private (Canadian Cancer Society/Cole Foundation, Charles Bruneau Foundation, Leukemia and Lymphoma Society of Canada) funding agencies, her laboratory has established a solid expertise in the field of T cell exhaustion, a differentiation pathway that limits optimal T effector cell functions and precludes memory T cell development. She is particularly involved in identifying the cytokine-dependent signaling pathways and transcription factors regulating T cell exhaustion during disease. She further aims to develop novel combined immunotherapeutic approaches that target inhibitory receptors and/or cytokine-dependent signaling pathways, to improve cure rates in cancer refractory patients and patients with primary immunodeficiencies. Hélène Decaluwe in also in recognized expert in the immune reconstitution of severe combined immunodeficiency patients treated by stem cell transplantation and aims to inform on the best therapeutic approaches to transplant these patients. Since the beginning of the current COVID-19 pandemic, her laboratory has been investigating T-cell immune correlates of protection to SARS-Cov-2, induced by natural infection and vaccination, through research initiatives supported by the Canadian Institutes of Health Research and the COVID-19 Immunity Task Force.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

Describe the research activity, including your role

Source of funding

Funds allocated to

Total dollar amount

Recurrence

Key dates

REinfection in COVid- 19 Estimation of Risk (RECOVER); NPI C Quach; co-investigator

Canadian Institutes of Health Research (CIHR)

Institution

$100,000-500,000

One-time event

Date interest arose:

June 2020

Date interest ended: May 2021

REinfection in COVid- 19 Estimation of Risk (RECOVER) - Phase 2 Vaccine; NPI C Quach; co-investigator

Public Health Agency of Canada (PHAC) -through the CITF

Institution

$500,000-1,000,000

One-time event

Date interest arose:

Apr 2021

Date interest ended: Mar 2023

Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study); NPI A Pham-Huy; co-PI

Children's Hospital Academic Medical Organization (CHAMO) Innovation fund

Institution

$50,000-100,000

One-time event

Date interest arose:

Apr 2021

Date interest ended: Mar 2022

Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study); NPI A Pham-Huy; co-PI

Physicians Services Incorporated Foundation (The PSI)

Institution

$100,000-500,000

One-time event

Date interest arose:

Apr 2021

Date interest ended: Mar 2024

Deciphering the immunopeptidomic landscape of COVID- 19 disease; NPI E Caron; co-investigator

Canadian Institutes of Health Research (CIHR)

Institution

$100,000-500,000

One-time event

Date interest arose:

Apr 2021

Date interest ended: Mar 2024

Novel therapeutic regimen to treat hemophagocytic lymphohistiocytosis; NPI H Decaluwe

Charles Bruneau Foundation (Mtl, QC)

Institution

$10,000-50,000

>1 time

Date interest arose:

Sept 2020

Date interest ended: Aug 2022

A two-cohort, open- label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still's disease (including systemic juvenile idiopathic arthritis and Adult onset Still's disease) or with MAS in Systemic lupus erythematous

SOBI

Institution

$10,000-50,000

>1 time

Date interest arose:

Oct 2021

Please provide any additional comments, if applicable:

Amounts declared are the amount to H. Decaluwe, not the total amount of the grants

Multiple grants applied for, and relevant to COVID-19 immune responses, are still pending (to CIHR and PHAC/CITF): CIHR CEPI Leadership Award for Excellence in Vaccine Research; IRYIS study: Immune Responses in Young ImmunoSuppressed Children to COVID19 vaccine; CHOIR study: Children and Older teens Immune Response to SARS-CoV-2 in Montreal

Interest in the role of JAK inhibitors for the treatment of severe COVID-19. Ideas proposed to the CIHR, to the FRQS and to Eli Lilly Canada, in the Spring of 2020. Project was initiated but did not receive funding.

2. Equity ownership Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual property Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

Describe the paid or voluntary work, including your role

Employer

Recurrence

Key dates

Invited to a Scientific Advisor Board on the role of baricitinib and monoclonal antibodies for the treatment of COVID-19

Eli Lilly Canada

One-time event

Date interest arose: Apr 24, 2021

Please provide any additional comments, if applicable:

Have not been contacted to sit on Eli Lilly Canada SAB since this event (one-time event). Master agreement signed for 3 years.

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

Describe the presentation

Source of funding (if applicable)

Funds allocated to

Total dollar amount

Recurrence

Key dates

Hyperinflammation and targeted immunotherapies in hemophagocytic lymphohistiocytosis. 76th Annual Canadian Society of Allergy and Clinical Immunology Scientific Virtual Meeting

Canadian Society of Allergy and Clinical Immunology

Directly to the researcher

$1,000-5,000

One-time event

Date interest arose: Oct 2021

How to target hyperinflammation in hemophagocytic lymphohistiocytosis, Pediatric Grand Rounds, Children Hospital Eastern Ontario, Ottawa

N/A

N/A

N/A

One-time event

Date interest arose: Dec 2021

Targeted therapies to control the cytokine storm in hemophagocytic lymphohistiocytosis. Pediatric Grand Rounds, Alberta Children's Hospital (Virtual), Calgary, Canada

N/A

N/A

N/A

One-time event

Date interest arose: Nov 2021

Combination therapy using ruxolitinib and emapalumab to treat familial HLH; Primary Immune Deficiency Treatment Consortium Think Tank - State of the Science Meeting, United States

N/A

N/A

N/A

One-time event

Date interest arose: Apr 2021

Immune Responses to SARS-Cov-2 mRNA vaccination in convalescent adults presented at the National Advisory Committee on Immunization weekly meeting

Public Health Agency of Canada

N/A

N/A

One-time event

Date interest arose: Apr 2021

Cytokine-targeted combination therapy to treat familial hemophagocytic lymphohistiocytosis. Bone Marrow Transplantation and Immune Deficiency Seminar Series - Cincinnati Children's Hospital Medical Center (Virtual), United States

Cincinnati Children's Hospital Medical Center

Directly to the researcher

$1,000-5,000

One-time event

Date interest arose: Oct 2020

Combination therapies targeting cytokines to treat hereditary lymphohistiocytosis. Primary Immune Deficiency Treatment Consortium Annual Workshop (virtual meeting), United States

N/A

N/A

N/A

One-time event

Date interest arose: May 2020

Future targets for combination therapy in hemophagocytic lymphohistiocytosis. 2019 Inborn Error Working Party Annual Meeting (European Bone Marrow Transplantation), United Kingdom

N/A

N/A

N/A

One-time event

Date interest arose: Oct 2019

6. Sponsored travel

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

Describe the travel

Source of funding (if applicable)

Funds allocated to

Total dollar amount

Recurrence

Key dates

Invited by the Consulat Général de France to tour 5 different Research Centers focused on Oncology in Lyon, Grenoble and Paris during one week. Elaborations of programs to increase partnerships between France and Quebec Research Centers

Consulat Général de France à Québec

Directly to the researcher

$1,000-5,000

One-time event

Date interest arose: Oct 2021

7. Hospitality Footnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

Describe the association, including your role

Organization

Funds allocated to

Total dollar amount

Recurrence

When the association happened

Founding member of the Clinical Immunology Network of Canada, a network of Canadian clinicians that are involved in the care of patients with primary immune deficiencies. Chair of the first Annual CINC Symposium to be held in Halifax in June 2022.

Multiple pharmaceutical companies financially support our Network.

Clinical Immunology Network - Canada (CINC)

Institution

$10,000- 50,000

>1 time

Date interest arose: Since 2021

Co-organiser of the Annual Symposiums of Montreal Immunology Meetings. Montreal Immunology Meetings is a non-profit organization that develops activities to foster collaborations and scientific interactions within Montreal between clinicians and scientists in the field of Immunology. We organize a yearly symposium, inviting 5-6 national and international speakers, and orchestrating student presentations and posters. Each year 200-220 participants attend the meeting.

Multiple pharmaceutical companies financially support our Network, including CSL Behring that was approached directly by me and supported our MIM symposiums for at least 3 years (maybe more)

Montreal Immunology Meetings (MIM)

Institution

$10,000- 50,000

>1 time

Date interest arose: Since 2014


Date interest ended: Dec 2021

Invited speaker at the Canadian Immunodeficiency Patient Organization

Canadian Immunodeficiency Patient Organization (CIPO)

N/A

N/A

>1 time

Date interest arose: Sept 2021

Active member of the Primary Immunodeficiency Treatment Consortium: a North-American consortium reuniting 42 distinct institutions working together to improve the care of children with immunodeficiencies

Primary Immunodefici ency Treatment Consortium

N/A

N/A

>1 time

Date interest arose: Since 2014

Active member of the Clinical Immunology Society and member of the Women in Clinical Immunology Sciences committee of the Clinical Immunology Society

Clinical Immunology Society

N/A

N/A

>1 time

Date interest arose: Since 2010

Active member of the European Society for Immunodeficiencies and former junior representative for Canada

European Society for Immunodeficiencies

N/A

N/A

>1 time

Date interest arose: Since before 2010

Active member of the Federation of Clinical Immunology Societies, CSI representative

Federation of Clinical Immunology Societies

N/A

N/A

>1 time

Date interest arose: Since 2021

Member of the Canadian Society for Immuology

Canadian Society for Immuology

N/A

N/A

>1 time

Date interest arose: Since 2010

Member of the Histiocyte Society

Histiocyte Society

N/A

N/A

>1 time

Date interest arose: Since 2020

Please provide any additional comments, if applicable:

Multiple patient groups / associations are involved within all of these networks / associations. To name a few: Jeffrey Modell Foundation, SCID Angels, Immune Deficiency Foundation, CGD Association of America, Wiskott Aldrich Foundation, Hyper IgM Foundation

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

Describe the statement, including where it was published

Funds allocated to

Total dollar amount

Recurrence

When the statement happened

Invited speaker for a live webinar organized by "COVID- 19 Resources Canada" and the Trottier Family Foundation on Covid vaccines and variants to answer questions of the general public

N/A

N/A

One-time event

Date interest arose: June 2021

10. Other relevant disclosures related to the guideline topic that do not fit the categories above Footnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Philippe De Wals

Département de médicine sociale et préventive
Québec, Quebec

Philippe De Wals is Professor at the Department of Social and Preventive Medicine, Laval University, in Québec City, Canada. Professor De Wals gained his Medical Degree and a Doctorate in Public Health in his home country of Belgium, at the Louvain Catholic University. His early academic and professional career combined epidemiology research studies at the School of Public Health at the Louvain Catholic University with the practice of general medicine. Between 1980 and 2000 he worked as an epidemiologist for EUROCAT, a European network of population-based registries for the epidemiologic surveillance of congenital anomalies. In 1990, he moved to Canada and became the Head of the Department of Community Health Sciences at the University of Sherbrooke. In 1997, he was appointed visiting Professor at the School of Public Health at the University of North Carolina in Chapel Hill, USA.

Professor De Wals' research is centered on the epidemiology of infectious diseases, reproductive abnormalities, and the assessment of health services and public health programs and policies. He is the author of over 150 published articles in scientific journals and has contributed several chapters to textbooks. Currently, Professor De Wals is a member of the research centers at Quebec University Hospital and the Sherbrooke University Hospital and is a medical advisor to the Quebec National Institute of Public Health. In 2011, he was appointed as Scientific Director of the Evaluation Platform on Obesity Prevention at the Quebec Cardiology and Pneumology Institute.

In 1990, Professor De Wals was awarded the Jean Van Beneden Prize in recognition of his excellent work in the public health field, and in 2005, he was elected to the Royal Academy of Medicine of Belgium.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
PI: Factors influencing decision-making on meningococcal vaccine programs Laval University,
Centre de recherché Clinique du CHU de Sherbrooke
Glaxo-Smith Kline, Pfiser, Sanofi
Institution $100,000-500,000 On-going research project Started 2016
PI: Burden of respiratory infections and otitis media among children in Nunavik IRSC and GSK Institution $100,000-500,000 On-going research project Started 2010
PI: Burden of respiratory infections and otitis media among children in Quebec GSK Institution $100,000-500,000 On-going research project Started 2012

Please provide any additional comments, if applicable:

All the research programs described are investigator-initiated grants in which sponsors have no control on the study design, collection, analysis and interpretation of date, and dissemination of results.

I am also co-investigator or collaborator in several research projects supported by recognized research funding organizations (i.e. IRSC, FQRS).

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Presentations to scientific meetings and conferences. Reimbursement of travel expenses and registration fees from research grants, university budgets or organizations independent from pharmaceutical companies Directly to the researcher N/A N/A Date interest arose: Dec 2018
Date interest ended: Nov 2019

Please provide any additional comments, if applicable:

No honorarium associated with these activities

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

Please provide any additional comments, if applicable:

I wrote scientific papers and reports, participated in the elaboration of statements (i.e. NACI and CIQ), gave presentations and lectures on vaccines that were totally independent from pharmaceutical companies.

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Eve Dubé

Québec National Institute of Public Health and the Research Center of the CHU-Québec
Québec, Quebec

Dr. Eve Dubé is a medical anthropologist. She is affiliated with Quebec National Institute of Public Health and the Research Center of the CHU-Québec. She is also an invited professor in anthropology at Laval University. Her research focuses on social, cultural and ethical issues around infectious diseases prevention. Most of her research aims at understanding why people accept, refuse or hesitate to receive vaccines and why healthcare providers adhere or not to vaccination recommendation for themselves, their families and their patients. She is the lead investigator of the Social Sciences and Humanities Network of the Canadian Immunization Research Network. From 2013 to 2014, she was a member of the World Health Organization (WHO) working group on vaccine hesitancy and she is currently part of the WHO Global Advisory Committee on Vaccine Safety where she is mainly involved in vaccine risk communication.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Vinita Dubey

Toronto Public Health

Dr. Vinita Dubey graduated from the University of Toronto's Public Health and Preventive Medicine Residency Program. She holds an Adjunct Professor appointment with the University of Toronto's Dalla Lana School of Public Health. Since 2006, she has been an Associate Medical Officer of Health for Toronto Public Health in Communicable Disease Control. Specializing with the Vaccine Preventable Disease program includes involvement in the school based vaccine program, immunization school assessment program which suspends students who are not up-to-date with required vaccines, adverse event following immunization investigations, and outbreak management including the 2017 mumps outbreak in Toronto which was the largest mumps outbreak the city has had in over 20 years. She also works as an emergency medicine physician in a small community hospital.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Kyla Hildebrand

University of British Columbia
Vancouver, British Columbia

Dr. Kyla Hildebrand is a Pediatric Clinical Immunology and Allergy specialist and Clinical Associate Professor in the Department of Pediatrics at the University of British Columbia (UBC). Her subspecialty training was completed at the Hospital for Sick Children and University of Toronto. She completed a Master of Community Health Sciences program from the Dalla Lana School of Public Health, University of Toronto. She is a Clinical Investigator at the BC Children's Hospital Research Institute and Director of the Pediatric Clinical Immunology and Allergy Residency Training Program at UBC.

Dr. Hildebrand's clinical work involves assessing and managing complex patients presenting with allergic and immunological disorders including children requiring hematopoietic stem cell transplantation. She has been engaged with the Special Immunization Clinic (SIC) Network at UBC since 2014. She is a collaborator at the UBC site in the Canadian Health Infant Longitudinal Development (CHILD) study, designed to advance knowledge about the genetic and environmental determinates of atopic disease to determine how early life exposures relate to health and disease outcomes.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Site Primary Investigator, BC Children's Hospital for the CONCOR Kids study. A randomized placebo control trial of COVID19
convalescent plasma in children.
nil N/A N/A N/A Date interest arose: Apr 2020
Date interest ended: Jan 2021
Co-Principal investigator, Special Immunization Clinic Network. COVID-19 Immunity Task Force: Optimizing COVID-19 immunization in patients with adverse events following immunization in the Special Immunization
Clinic Network (S106)
Canadian Immunization Research Network/Coalition for Epidemic Preparedness Innovations (CEPI) Institution $100,000- 500,000 One-time event Date interest arose: Jan 2021
Date interest ended: Ongoing
Co investigator, COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient Patients – VISID study COVID19
Immunity Task Force
Institution >$1,000,000 One-time event Date interest arose: 2021
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

CONCOR-Kids Study closed in early 2021 due to low number of enrolments across the country.

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Volunteer; Medical expert providing input and review of a publicly funded PIDD smart phone application - BC Provincial Blood Coordinating Office BC Provincial Blood Coordinating Office >1 time Date interest arose: 2018
Date interest ended: 2019
Volunteer; Medical expert, Children's and Women's Health Centre 1) Emergency Blood Management Committee and 2) PIDD Working group member. Provincial Health Services Authority >1 time Date interest arose:
1) 2019
2) May 2020
Date interest ended:

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
COVID-19 vaccine webinar, co- presenter Canadian Society of Allergy and Clinical
Immunology
N/A <$1,000 One-time event Date interest arose: Jan 2021
Date interest ended: Feb 24, 2021
COVID-19 vaccine webinar, co- presenter. Volunteer, not paid Canadian Immunedeficiency Patient Organization N/A N/A One-time event Date interest arose: Feb 2021
Date interest ended: Feb 2021

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Member, Board of Directors of the CSACI Canadian Society of Allergy and Clinical Immunology Institution N/A >1 time Date interest arose: 2017
Date interest ended: Ongoing
Member, Medical Advisory Board Canadian Immunedeficiency Organization Institution N/A >1 time Date interest arose: 2021
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

The CSACI receives sponsorship for the annual scientific meeting from several pharmaceutical companies. Amounts vary depending on level of sponsorship but are less than <$100,000 per sponsor.

CIPO is a patient advocacy organization that receives corporate sponsorship from Takeda and Grifols companies that sell immunologlobulin products.

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Kristin Klein

Alberta Health Services
Edmonton, Alberta

Dr. Kristin Klein is public health and preventive medicine specialist based out of Edmonton, Alberta. She holds two positions with Alberta Health Services, serving as Associate Provincial Medical Officer of Health for Communicable Disease Control and as a local Medical Officer of Health for Northern Alberta. Her educational background includes a Bachelor of Science from the University of Calgary, a medical degree and fellowship training in Public Health and Preventive Medicine from the University of Alberta. Prior to her role with AHS, Dr. Klein served as the Deputy Medical Officer of Health for the Government of Alberta. She has contributed to several provincial and national committees including representing the Council of Chief Medical Officers of Health as liaison member to NACI. She also holds a clinical appointment with the Faculty of Medicine and Dentistry at the University of Alberta.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Jesse Papenburg

McGill University Health Centre
Montreal, Quebec

Dr. Jesse Papenburg is an Assistant Professor of Pediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. He practices Pediatric Infectious Diseases and Medical Microbiology at the Montreal Children's Hospital of the McGill University Health Centre.

Dr. Papenburg obtained his medical degree from McGill University and completed residency and subspecialty training at the Montreal Children's Hospital. He then completed a research fellowship on the molecular virology of RNA respiratory viruses at Laval University and a MSc in epidemiology at McGill. As a clinician scientist, Dr. Papenburg's research is on the epidemiology of viral respiratory infections, with a focus on diagnostics to improve treatment and outcomes. He actively contributes to national and provincial guidelines on RSV immunoprophylaxis and influenza antiviral treatment.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Site Principle Investigator (PI), Industry-led trial
“A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants.”
MedImmune Institution $10,000-50,000 One-time event Date interest arose: Jan 2017
Date interest ended: Mar 2019
Site PI, Investigator-initiated Research grant
“CaRESS: Canadian RSV Evaluation Study of Synagis®.”
AbbVie Institution $100,000-500,000 One-time event Date interest arose: Jan 2014
Date interest ended: Dec 2017
Site PI, Industry-led trial
“QHD04 Phase II, randomized, staged, modified double-blind, multi-center study in the United States and Canada to evaluate the safety and immunogenicity of 3 dosages of QIV-HD administered intramuscularly in children 6 months to 17 years of age.”
Sanofi Pasteur Institution $10,000-50,000 One-time event Date interest arose: Jan 2019
Date interest ended: Apr 2020
Site PI, Industry-led trial
“A Phase 3 Randomized, Double-blind, Placebo-controlled Study to evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY).”
MedImmune/AstraZeneca Institution $10,000-50,000 One-time event Date interest arose: Oct 2019
Date interest ended: Mar 2020
Site PI,
Investigator Initiated study
“INFORM: International, multi-centre, observational study to determine the molecular heterogeneity of RSV in children.”
MedImmune Institution $10,000-50,000 One-time event Date interest arose: Jan 2018
Date interest ended: July 2022
Site PI, Industry-led study
Primary author on published manuscripts.
“Impact of the lack of immunoprophylaxis for severe respiratory syncytial virus disease in infants born at 33 to 35 weeks gestational age: An observational, non-interventional study in Québec”
MedImmune Institution $50,000-100,000 One-time event Date interest arose: Jan 2016
Date interest ended: Dec 2018
Medical Lead, scientific steering committee, i.e., to ensure the scientific validity of the methodology and the interpretation of the results.
“Impact of the lack of immunoprophylaxis for severe respiratory syncytial virus disease in infants born at 33 to 35 weeks gestational age: An observational, non-interventional study in Québec”
MedImmune Institution $10,000-50,000 One-time event Date interest arose: Jan 2016
Date interest ended: Dec 2018

Please provide any additional comments, if applicable:

N.B. I have moved my roles on the “Impact of the lack of immunoprophylaxis for severe respiratory syncytial virus disease in infants born at 33 to 35 weeks gestational age: An observational, non-interventional study in Québec” study from section 4 to Section 1, to better reflect my participation/roles/activities on the study. I also separated my role as site PI and my role as Medical Lead of the Scientific Steering Committee.

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Anne Pham-Huy

Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario

Dr. Anne Pham-Huy completed her medical degree at the University of Ottawa in 2003 and her subspecialty training in pediatric infectious diseases at McGill University in 2008. She also pursued additional training in clinical immunology.  Dr. Pham-Huy has been at the Children's Hospital of Eastern Ontario (CHEO) since 2009. She is the lead physician for the primary immunodeficiency clinic at CHEO. Her research interests include the diagnosis and management of primary immunodeficiencies, infections in the immunocompromised host and immunization in special populations. She is the program director for the pediatric infectious diseases training program.  She is also the current chair for Immunize Canada, a not-for-profit coalition of organizations with a specific interest in promoting the understanding and use of vaccines.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study) CHAMO Innovation Fund Institution $80,558 One-time event Date interest arose: Date interest ended:
COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient Patients – (VISID Study) COVID-19 Immunity Task Force (CIFT) Institution $28,600 from $2,468,279 total multicentre One-time event Date interest arose: Date interest ended:
Natural Evolution of Serum Antibodies in Children and Adults with SARS-CoV-2 and Household Contacts: Persistence of Antibody Titers to COVID-19 in Households (PATCH Study) Ontario COVID-19 Rapid Research Fund Funding, Provincial Innovation Fund CHAMO COVID-19 Innovation Fund Institution $926,492
$245,000
$89,973
One-time event Date interest arose: Date interest ended:
Optimizing the clinical management of patients with adverse events following COVID-19 vaccination in Special Immunization Clinic Network Canadian Immunization Research Network Institution TBD One-time event Date interest arose: Date interest ended:
Optimizing varicella immunization in children and youth with solid organ transplants to prevent disease and improve long-term health – funded through the Canadian Immunization Network Canadian Immunization Research Network Institution $125,174 One-time event Date interest arose: Date interest ended:
Special Immunization Clinic Network to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination and those with adverse events following immunization (AEFI) as a platform for observational
research
CIHR Institution $133,000 >1 time Date interest arose:
Date interest ended:

2. Equity ownership Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual property Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work Footnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Immunization in primary and secondary immunodeficiencies: To vaccinate or not to vaccinate? Annual scientific meeting - Virtual Canadian Society of Allergy and Clinical Immunology (CSACI) Directly to the researcher $500 One-time event Date interest arose: Oct 24, 2020
Date interest ended:

6. Sponsored travel Footnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. Hospitality Footnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations Footnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients with Inflammatory Bowel Disease (IBD). Part 1: Live Vaccines (To be published in Gastroenterology and J Can Assoc gastroenterol N/A N/A N/A Date interest arose:
Date interest ended:
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients with Inflammatory Bowel Disease (IBD). Part 2: Inactivated Vaccines (To be published in Gastroenterology and J Can Assoc gastroenterol N/A N/A N/A Date interest arose:
Date interest ended:

10. Other relevant disclosures related to the guideline topic that do not fit the categories above

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Describe the interest Funds allocated to Total dollar amount Recurrence When the interest happened
Chair of Immunize Canada N/A N/A N/A Date interest arose:
Date interest ended:
Dr. Beate Sander

Toronto General Hospital
Toronto, Ontario

Beate Sander, PhD, is a Scientist at Public Health Ontario (PHO), Assistant Professor at the University of Toronto, Adjunct Faculty at York University, and Adjunct Scientist at the Institute for Clinical Evaluative Sciences (ICES).

Beate's research interests lie in the area of economic evaluation with a focus on infectious diseases. She is leading multidisciplinary teams evaluating Zika and West Nile virus mitigation strategies using data-driven simulation models, and is linking laboratory with population-based administrative data, enabling novel approaches to study the burden of infectious diseases.

Beate served on the board of the Society of Medical Decision Making (SMDM) and is an editorial board member of the "Medical Decision Making" journal. Beate provides scientific advice to decision-makers and advisory bodies and serves on scientific working groups and networks.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Ms. Susan Smith

Alberta Health
Edmonton, Alberta

Ms. Smith is the Manager for Immunization Policy at Alberta Health. She has over thirty years of Public Health experience primarily focused on public health programs, immunization, and communicable disease control. Her roles have included front line generalist practice, nurse consultant, clinical development nurse (immunization and communicable disease control), and manager for immunization policy at Alberta Health.

Her experience includes providing immunizations, orienting/educating staff and clients on immunization and communicable disease issues, ensuring quality of immunization programs, and following up on notifiable diseases providing her with a strong clinical and operational background in public health immunization programs.

Currently, as manager for immunization policy Ms. Smith is responsible for the development and implementation of immunization policy in Alberta. This includes, coordinating and facilitating the work of the Alberta Advisory Committee on Immunization. In addition, in this role she has chaired and facilitated a number of immunization working groups comprised of medical officers of health, infectious disease physicians, nurse leaders and program staff to update and revise Alberta's immunization policy including immunization recommendations for solid organ transplant recipients, hematopoietic stem cell transplant recipients, and immunocompromised individuals; and recommendations for rotavirus, hepatitis B, varicella, and measles containing vaccines.

Ms. Smith has also been a member of in the Canadian Nursing Coalition for Immunization for the past two years and presented at the 2016 Canadian Immunization Conference.

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Secretariat to Alberta Advisory Committee on Immunization Alberta Health Meets 2 to 3 times per year Date interest arose: Sept 2019
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

The Alberta Advisory Committee on Immunization (the Committee) is a multidisciplinary expert committee, reporting to the Deputy Minister of Health through the Chief Medical Officer of Health, with the mandate to provide ongoing and timely medical, scientific and public health advice related to immunization

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Presentation to Alberta Advisory Committee on Immunization Rabies Vaccine and RIG N/A N/A  N/A >1 time Date interest arose: Jan 2019
Date interest ended: Oct 2019
Secretariat to Alberta Advisory Committee on Immunization. COVID vaccine recommendations - use of AstraZeneca (age and VITT), priorities of vaccine rollout, extending intervals, shortening intervals for specific groups, use in adolescents, immunization after COVID- 19 vaccine, co-administration and simultaneous immunization, mixed schedules N/A N/A N/A >1 time Date interest arose: Feb to present 2021
Date interest ended:

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Manager, Immunization Policy Alberta Health N/A N/A N/A Date interest arose: Sept 2018
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

Alberta Health is my place of employment. My major responsibility is ensuring Alberta's immunization policy is current through review of current literature, research, and consultation. As well, as responding to health care professional inquiries on Alberta's Immunization Policy. Within the manager role is the responsibility to the Alberta Advisory Committee on Immunization as secretariat.

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
Alberta Immunization Policy N/A N/A N/A Date interest arose:
Date interest ended:

Please provide any additional comments, if applicable:

All immunization policies are published on the web https://www.alberta.ca/alberta-immunization-policy.aspx

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Dr. Sarah Wilson

Public Health Ontario
Toronto, Ontario

Dr. Sarah Wilson is a public health physician/medical epidemiologist at Public Health Ontario PHO where she works closely with the Immunization and Vaccine-Preventable Diseases team within the Communicable Diseases and Emergency Preparedness Response Department. In this role, she provides support to the surveillance of vaccine-preventable diseases, immunization coverage, vaccine safety, outbreak management, and participates in applied research. Sarah's research interests include applied vaccine program evaluation and immunization coverage assessment using a range of data sources including both routine surveillance and administrative data. She is a Fellow of the Royal College of Physicians and Surgeons in Public Health and Preventive Medicine and a graduate of the Canadian Field Epidemiology Program. She is an Assistant Professor at the Dalla Lana School of Public Health at the University of Toronto and an Adjunct Scientist at ICES (formerly known as the Institute for Clinical Evaluative Sciences).

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
I am the Public Health Ontario (PHO) representative on Immunize Canada. I attend quarterly meetings to understand and contribute to discussions about immunization promotion (typically not vaccine specific). Immunization Canada N/A N/A N/A Date interest arose: Nov 2019
Date interest ended: Ongoing
I am affiliated with the University of Toronto's Centre for Vaccine Preventable Diseases as a member of its Education committee. I attend meetings and provide input on how to improve immunization competencies among health care providers and trainees. Centre for Vaccine-Preventable Diseases, University of Toronto N/A N/A N/A Date interest arose: Apr 2017
Date interest ended: Ongoing

Please provide any additional comments, if applicable:

I am listing my affiliation with the University of Toronto Centre for Vaccine-Preventable Diseases here as I understand the Centre has recently received funding from vaccine manufacturers to support post-doctoral fellowships that would be funded through the Centre. I will not be involved in the administration of the funds and will not receive any of the funds. I am unsure of the specific dollar amount as a formal announcement is forthcoming.

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2.  Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories above

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Describe the interest Funds allocated to Total dollar amount Recurrence When the interest happened
Employee of Public Health Ontario N/A N/A >1 time Date when interest arose: June 2012
Date when interest ended: Ongoing

Please provide any additional comments, if applicable:

I receive a salary as an employee of Public Health Ontario. My role at Public Health Ontario includes providing scientific and technical advice to the Ontario Ministry of Health in regards to the implementation and monitoring of immunization programs.

Executive secretary

Dr. Matthew Tunis

Liaison representatives

Association of Medical Microbiology and Infectious Disease Canada
Dr. Jeannette Comeau
Halifax, NS

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants, Co-Investigator GlaxoSmithKline Biologicals Institution $100,000-500,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

A Phase 3, multicenter, randomized, double-blind, active comparator controlled study to elevate the safety and tolerability of V114 in healthy infants (PNEU - LINK), Co-Investigator Merck Canada Inc. Institution $100,000-500,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

A phase III, observer-blind, randomized, multicountry study to assess the reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK's oral live attenuated human rotavirus (HRV) vaccine as compared to the lyophilized formulation of the GSK's HRV vaccine, when administered as a 2-dose vaccination in infants starting at age 6-12 weeks, Co-Investigator GlaxoSmithKline Biologicals Institution $100,000-500,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

A Phase I, randomized, modified double-blind, parallel-group, active-controlled, multi-center, multiple formulation, dose ranging study to describe the safety and compare the immunogenicity of 4 investigational formulations of Tdap vaccine to ADACEL®when administered as a 1- or 2-dose schedule via intramuscular route in healthy, young adults in Canada, Co-Investigator Sanofi Pasteur Ltd. Institution $100,000-500,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age, Co-Investigator Janssen Research & Development LLC Institution $50,000-100,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

A Phase II, randomized, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers, Co-Investigator GlaxoSmithKline Biologicals Institution $50,000-100,000 One-time event

Date interest arose: 2019

Date interest ended: 2024

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work Footnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

Please provide any additional comments, if applicable:

I have never received speaking fees for any presentations/lectures. I have received travel honorariums for conferences and lectures, but never any funds from a pharmaceutical company or related third party.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

Please provide any additional comments, if applicable:

I have received funds from WHO for travel to conferences and meetings, and travel honorariums from conferences directly, but never any funds from a pharmaceutical company or related third party.

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Canadian Association for Immunization Research and Evaluation
To be determined

Canadian Immunization Committee
Dr. Monika Naus
Vancouver, BC

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Meningococcal vaccine study led by Dr. Sadarangani, I am a coinvestigator Multiple, including BCIC, CIHR-CIRN Institution $50,000-100,000 One-time event Date interest arose: 2018
Date interest ended: Ongoing
Pneumococcal vaccine study (1 dose), led by Dr. Sadarangani, I am a coinvestigator Multiple, including CIHR-CIRN Institution $50,000-100,000 One-time event Date interest arose: 2018
Date interest ended: Ongoing
HPV vaccine studies led by Dr. Ogilvie, I am a coinvestigator Multiple, including CIHR Institution Total funds will be in the range of $10 for a variety of projects Multiyear funding Ongoing

Please provide any additional comments, if applicable:

No personal financial benefit of participation. I am not the holder of these funds.

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

Please provide any additional comments, if applicable:

I do routinely give presentations in the CME category for a variety of audiences including family physicians and other immunization service providers.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
I am routinely involved in development of guidelines for the use of vaccines for disease prevention and control, communication of these guideline, etc. in my role as a public health physician at a provincial level N/A N/A >1 time Date interest arose: Throughout the past 5 years
Date interest ended:

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Please provide any additional comments, if applicable:

I am a full-time employee of the University of British Columbia funded by the BC Centre for Disease Control in a grant tenure position. I am full faculty at UBC and a Professor. My full-time service role with BCCDC is as the Medical Director of the Communicable Diseases and Immunization Service and Medical Head for Immunization Programs and Vaccine Preventable Diseases. All of the activities listed above are in the context of these positions.

Canadian Indigenous Nurses Association

Ms. Lea Bill
Siksika, AB

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Canadian Public Health Association
Ms. Lucie Marisa Bucci
Ottawa, ON

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
International Federation on Ageing Institution <$1,000 One-time event Date interest arose: June 24, 2019
Date interest ended: June 25, 2019

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Immunize Canada Institution $100,000-500,000 One-time event Date interest arose: Ja 2019
Date interest ended: Dec 2019

Please provide any additional comments, if applicable:

Immunize Canada receives sponsorships and educational grants from various pharmaceutical companies to undertake its educational and promotional activities. These funds go towards the operation of the coalition and Immunize Canada retains editorial control over all its' products. These grants and sponsorships are obtained on a yearly basis.

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Canadian Paediatric Society
Dr. Dorothy Moore
Montréal, QC

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Canadian Paediatric Society Infectious Diseases and Immunization Committee Voluntary, not paid N/A Date interest arose: 1999
Date interest ended: Ongoing

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Vaccine hesitancy one-day workshop Canadian Paediatric Society Honorarium plus expenses $1,000-5,000 (total for four workshops excl virtual) >1 time

Date interest arose:
Dec 3, 2018
Mar 26, 2019
Oct 30 2019
Jan 20, 2020
Nov 25-26, 2020 (virtual)
Date interest ended:

Please provide any additional comments, if applicable:

Received $1000.00 honorarium (for all three) and travel expenses

6. Sponsored travel

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Canadian Immunization Conference 2018 Montreal Children's Hospital Personal Research Fund N/A <$1,000 One-time event Date interest arose:
Dec 2018

Please provide any additional comments, if applicable:

Reimbursement for registration fees and travel expenses

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Canadian Paediatric Society (b) member N/A N/A N/A Date interest arose: 1984
Date interest ended: Ongoing
Association of Medical Microbiology and Infectious Diseases, Canada (b) member N/A N/A N/A Date interest arose: 1985
Date interest ended: Ongoing
Infectious Diseases Society of America (b) member N/A N/A N/A Date interest arose: 1986
Date interest ended: Ongoing

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Canadian Pharmacists Association
Ms. Amanda Ung
Toronto, ON

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role Employer Recurrence Key dates
Medical Communications Team Supervisor for Johnson & Johnson USA COVID 19 Vaccine (FDA Emergency Use Authorization) Alphanumeric Systems Inc (contract vendor that hired me for JNJ USA project) One-time event Date interest arose: Oct 19, 2020
Date interest ended: July 21, 2021

Please provide any additional comments, if applicable:

Johnson & Johnson COVID 19 Vaccine was never approved for use by Health Canada despite that the manufacturer received Interim Order. My work was primarily to support JNJ USA as one of the Team Supervisors. As Team Supervisor, my role is primarily people management and to ensure performance metrics are met. E.g. coaching, mentoring, performance reviews, attendance, staffing, recruitment, terminations, client liaison, communication metrics are hitting 95% of key performance indicators (speed of response, accuracy of information, documentation of customer interactions, complaints)

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Center for Disease Control and Prevention
Dr. Amanda Cohn
Atlanta, Georgia, USA

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Council of Chief Medical Officers of Health
Dr. Martin Lavoie
Vancouver, BC

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactc agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation Source of funding (if applicable) Funds allocated to Total dollar amount Recurrence Key dates
Presentation at immunization conference related to my role as Deputy Chief Medical Officer of Health at Government of Alberta Travel, accommodations and registration costs covered by provincial or federal government or agency N/A N/A N/A Date interest arose:
Date interest ended: 

Please provide any additional comments, if applicable:

2016 Canadian Immunization Conference - presentation on Security of Vaccine Supply

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published Funds allocated to Total dollar amount Recurrence When the statement happened
Media interviews as Chief Medical Health Officer N/A N/A N/A Date interest arose:
Date interest ended:

Please provide any additional comments, if applicable:

Part of my duties in the role of Chief Medical Health Officer for Fraser Health (August 2017- July 2020) was being an official spokesperson on public health issues. I spoke to the media on a regular basis. During media interviews, we refrain from using brand names, but we do promote immunization in general and often specifically mentioning vaccine products generically.

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Indigenous Physicians Association of Canada
Dr. Evan Adams
Ottawa, ON

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees Footnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Describe the interest Funds allocated to Total dollar amount Recurrence When the interest happened
I am an employee of the federal government - FNIHB-HQ, Indigenous Services Canada N/A N/A N/A

Date interest arose: May 11 2020

Date interest ended: May 10 2022

Society of Obstetrics and Gyneacologists
Dr. Eliana Castillo
Calgary, AB

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Canadian Nurses Association

Ms. Lorette Dupuis
Ottawa (Ontario)

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in researchFootnote *

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention

2. Equity ownershipFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual propertyFootnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary workFootnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking feesFootnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travelFootnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. HospitalityFootnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associationsFootnote *

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic

9. Public statements about the guideline topicFootnote *

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

College of Family Physicians of Canada

Dr. Jia Hu
Calgary (Alberta)

Disclosure of Affiliations and Interests from the last 3 years

1. Participation in research

Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Research that will be (or is likely to be) a component of a guideline recommendation on a topic
  2. Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
  3. Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role Source of funding Funds allocated to Total dollar amount Recurrence Key dates
Barriers and facilitators for adherence to COVID-19 public health measures and vaccination amongst Albertans. 
Role: Principal Investigator
Alberta Innovates - National Partnered R&I Initiatives  N/A $392,080 N/A Date interest arose: Aug 1, 2020
Date interest ended: July 31, 2021
Interventions to promote adherence to COVID-19 public health recommendations.
Role: Principal Investigator
Clinical Research Fund  N/A $50,000 N/A Date interest arose: Sept 1, 2020
Date interest ended: Aug 31, 2022
Evaluation of COVID-19 public health messaging to inform a COVID-19 vaccine confidence campaign. 
Role: Principal Investigator 
Alberta Innovates / Pfizer Alberta Collaboration in Health Fund - ImplementAB.digH Program N/A $529,500 N/A Date interest arose: Decr 1, 2020
Date interest ended: Nov 30, 2021
Barriers for COVID-19 vaccination amongst healthcare professionals in long-term care and homecare settings. 
Role: Co-applicant 
Public Health Agency of Canada – Immunization Partnership Fund N/A $500,000 N/A Date interest arose: July 1, 2021
Date interest ended: Mar 31, 2022
Increase uptake of COVID-19 and routine vaccinations among school-aged children in Alberta.
Role: Partner/ In-Kind Support 
Public Health Agency of Canada – Immunization Partnership Fund N/A $500,000 N/A Date interest arose: Oct 1, 2021
Date interest ended: Mar 31, 2023
Machine learning and natural language processing to analyze vaccine attitudes on social media.
Role: Principal Investigator
Vaccine Confidence Fund N/A $250,000 USD N/A Date interest arose: Sept 23, 2021
Date interest ended: Jan 31, 2022

Please provide any additional comments, if applicable:

As the CEO/Chair of 19 To Zero, I lead a great deal of vaccine uptake related work, particularly for COVID-19. These grants are largely focused on increasing COVID-19 vaccine uptake, although some of the PHAC grants will focus on other routine vaccinations as well.

2. Equity ownership Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

3. Intellectual property Footnote *

Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

4. Paid and voluntary work Footnote *

Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Employment in any capacity by the manufacturer of a health technology assessment under consideration
  2. Membership on a board of directors for a manufacturer of a health technology under consideration

5. Scientific meetings/lectures and speaking fees Footnote *

Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
  2. Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
  3. Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.

6. Sponsored travel Footnote *

Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party

7. Hospitality Footnote *

Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Example

  1. Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign

8. Sponsorship or associations

Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
  2. Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role Organization Funds allocated to Total dollar amount Recurrence When the association happened
Develop a digital platform to promote vaccine uptake by understanding the early signals of public vaccine trust and distrust. 
Role: Principal Investigator
Sanofi N/A $40,000 N/A Date interest arose: Nov 3, 2020
Date interest ended: June 30, 2021
Develop a digital platform to promote vaccine uptake by understanding the early signals of public vaccine trust and distrust.
Role: Principal Investigator
Merck  N/A $40,000 N/A Date interest arose: Oct 5, 2020
Date interest ended: May 31, 2021
Develop a digital platform to promote vaccine uptake by understanding the early signals of public vaccine trust and distrust.
Role: Principal Investigator
GSK N/A $40,000 N/A Date interest arose: July 10, 2020
Date interest ended: July 10, 2025
Vaccine confidence campaign to promote COVID-19 vaccination amongst low-income essential workers. 
Role: Principal Investigator 
Moderna  N/A $200,000 N/A Date interest arose: June 1, 2021
Date interest ended: June
The development and amplification of a Canada-wide COVID-19 vaccine confidence campaign. 
Role: Principal Investigator 
Shoppers Drug Mart N/A $200,000 N/A Date interest arose: July 7, 2021
Date interest ended: July 7, 2022
The development and amplification of a Canada-wide COVID-19 vaccine confidence campaign. 
Role: Principal Investigator 
Suncor  N/A $200,000 N/A Date interest arose: June 7, 2021
Date interest ended: June 7, 2022
Vaccine confidence campaign to promote COVID-19 vaccination amongst Regional Municipality of Wood Buffalo (RMWB) residents.
Role: Principal Investigator 
Suncor  N/A $80,000 N/A Date interest arose: Sept 15, 2021
Date interest ended: Sept 15, 2022 
Improving trust in pharmacy-delivered vaccines and shaping public perception around vaccinations.
Role: Principal Investigator 
GSK  N/A $175,000 N/A Date interest arose: April 12, 2021
Date interest ended:

Please provide any additional comments, if applicable:

I am the Chair/CEO of 19 To Zero, a not-for-profit that has been primarily focused on increasing COVID-19 vaccine uptake. 19 To Zero has received funding from various pharmaceutical and non-pharmaceutical (e.g., oil & gas) companies to do vaccine uptake campaigns.

9. Public statements about the guideline topic

Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?

Examples

  1. Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
  2. Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended

Please provide any additional comments, if applicable:

I do speak to the media on a fairly regular basis on a variety of topics, but they do not generally veer towards specific vaccine recommendations – in other words, I generally try to endorse and shore-up recommendations that NACI already makes.

10. Other relevant disclosures related to the guideline topic that do not fit the categories above Footnote *

Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?

Ex-officio representatives

Biologics and Genetic Therapies Directorate
Dr. Celia Lourenco
Health Canada
Ottawa, ON

Centre for Immunization Readiness (CIR)
Ms. Erin Henry
Public Health Agency of Canada
Ottawa, ON

Vaccine Safety
Ms. Susanna Ogunnaike-Cooke
Public Health Agency of Canada 
Ottawa, ON

COVID-19 Epidemiology and Surveillance
Ms. Diane MacDonald
Public Health Agency of Canada 
Ottawa, ON

Directorate of Force Health Protection
National Defense and the Canadian Armed Forces
Vincent Beswick-Escanlar
Ottawa, ON

National Microbiology Laboratory
Dr. Guillaume Poliquin
Public Health Agency of Canada
Winnipeg, MB

First Nations and Inuit Health Branch
Dr. Tom Wong
Indigenous Services Canada
Ottawa, ON

Marketed Health Products Directorate
Ms. Kelly Robinson
Health Canada
Ottawa, ON

Public Health Ethics Consultative Group (PHECG)
Ms. Mireille Lacroix
Ottawa, ON

Footnote *

None to declare

Return to footnote * referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: